冠心病血清同型半胱氨酸水平的变化及临床意义分析

Changes of Serum Homocysteine Levels in Coronary Heart Disease and Its Clinical Significance

目的探析冠心病血清同型半胱氨酸水平的变化及临床意义。方法方便选取2017年7月—2018年3月期间来该院进行体检63例患者,按其体检后是否诊断出冠心病将其分为冠心病组和对照组,其中冠心病组33例,对照组30例,分别采集每组实验人员外周静脉血,检测各组人员体内同型半胱氨酸水平,分析病变程度。结果冠心病组中SAP组(15.30±4.06)μmol/L、AMI组(29.22±4.99)μmol/L和UAP组(20.34±5.68)μmol/L血清同型半胱氨酸水平比较依次增高,3组相比差异有统计学意义(P<0.05),且冠心病组血清同型半胱氨酸水平明显高于对照组(7.23±2.13)μmol/L中的健康人员,组间比较差异有统计学意义(P<O.01)。结论血清同型半胱氨酸水平的高低与冠心病病变程度紧密相关,在临床上,血清同型半胱氨酸水平在评估冠心病病变程度上具有积极意义。

Objective To explore the changes and clinical significance of serum homocysteine levels in patients with coronary heart disease. Methods 63 patients were enrolled conveniently in the hospital from July 2017 to March 2018. According to whether they were diagnosed with coronary heart disease after physical examination, they were divided into coronary heart disease group and control group. Among them, 33 cases were coronary heart disease group. 30 patients in the control group, peripheral venous blood was collected from each group of experimental personnel, homocysteine levels were measured in each group, and the degree of lesions was analyzed. Results Serum homocysteine levels in the SAP group（15.30±4.06）μmol/L, AMI group（29.22±4.99）μmol/L and UAP group（20.34±5.68）μmol/L in coronary heart disease group, the proportions increased sequentially, and the difference between the three groups was significant（P〈0.05）. The homocysteine level in the coronary heart disease group was significantly higher than that in the control group（7.23±2.13）μmol/L. There was a statistically significant difference（P〈0.01）. Conclusion The level of serum homocysteine is closely related to the severity of coronary heart disease. Clinically, serum homocysteine level has positive significance in assessing the severity of coronary heart disease.